Clinical profile and early therapeutic response to cabergoline of patients with hyperprolactinemia in a Cameroonian population

Etoga, Martine Claude Etoa; Sobngwi, Eugène; Ngoune, Pelagie; Doh, Emmanuella; Mekobe, Francine Mendane; Mbango-Ekouta, Noel; Dehayem, Mesmin; Foumane, Pascal; Mbanya, Jean Claude

doi:10.11604/pamj.2020.35.2.12883

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In sub-Saharan Africa in general, its incidence and prevalence are poorly defined. It remains an infrequent pathology; the various studies in the literature such as that of N'guessan in Côte d'Ivoire in 2003 [5], Seck in Senegal in 2003 [6], Mariko in 2017 in Mali [7], Azhar in Morocco in 2017 [8], Ma in Niger in 2018, and Etoga in Cameroon in 2020 [9], the actual frequency was not calculated and discussed. In 2020, Sedzro [10], in a study of pituitary adenomas, found that 66.67% of the 12 cases of pituitary adenomas identified were prolactinomas.…”

Section: Introductionmentioning

confidence: 99%

Hyperprolactinemia in Hospitals in Lomé: Diagnostic and Therapeutic Aspects

Toyi,

Lihanimpo,

Kossi

et al. 2024

OJIM

View full text Add to dashboard Cite

Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 -50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.

show abstract

Section: Introductionmentioning

confidence: 99%